Published in AIDS Vaccine Week, June 30th, 2003
"Although most HIV-1 infections worldwide result from heterosexual transmission, most vaccine candidates have focused on induction of systemic immunity and protection," explained Zandrea Ambrose and colleagues at the University of Washington in Seattle, Tulane University in New Orleans, Duke University in Durham, North Carolina, and Therion Biologics in Cambridge, Massachusetts.
A vaccine regimen combining systemic priming and mucosal boosting produced effective...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.